Redwood AI Corp. (CSE: AIRX) (OTCQB: RDWCF) (Frankfurt: Y0N) has announced a non-binding letter of intent to explore the acquisition of Vancouver-based Quantum.IQ, an AI-driven quantum cybersecurity company focused on preparing organizations for emerging quantum-enabled cyber threats. The proposed transaction would see Redwood acquire all outstanding shares of Quantum.IQ in exchange for up to 14 million Redwood common shares, including milestone-based consideration, with all shares subject to a staged escrow release schedule over 24 months.
Quantum.IQ's post-quantum cryptography platform is designed to assist government, defense, financial services and critical infrastructure organizations in assessing cryptographic vulnerabilities, planning migration to quantum-resistant security systems and monitoring ongoing cybersecurity readiness. The acquisition, which remains subject to due diligence, definitive agreements, regulatory approvals and other customary closing conditions, could expand Redwood's capabilities in cryptographic intelligence, quantum-readiness assessment and cybersecurity planning, complementing its broader focus on artificial intelligence and advanced computational technologies.
The news is significant because quantum computing poses a potential threat to current encryption standards, and organizations are increasingly seeking solutions to protect sensitive data against future quantum attacks. By acquiring Quantum.IQ, Redwood AI positions itself at the intersection of AI and quantum cybersecurity, a niche that is expected to grow as quantum computing advances. For investors and industry observers, this move signals Redwood's strategic expansion beyond its core AI-driven chemistry R&D into the cybersecurity space, potentially opening new revenue streams and market opportunities.
Redwood AI uses advanced artificial intelligence to accelerate chemistry R&D, with the aim of assisting in drug discovery and development, and furthering defense and safety solutions. The Company combines expertise in chemistry, AI, and manufacturing to streamline drug synthesis and scale-up. Redwood AI's platform is designed to enable faster, more efficient development of new therapies and chemistry-driven applications. For more information, visit https://redwoodai.com/.
The full press release is available at https://ibn.fm/D0lb6.
